In a 45-year-old male with prediabetes, dyslipidemia, hypertension, and daily alcohol consumption of 42 g, which term most specifically describes his steatotic liver disease according to the American Diabetes Association (ADA) consensus report on screening for metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes?

MetALD (Metabolic dysfunction and alcoholic liver disease) is the most specific term for this patient's steatotic liver disease.

This patient meets the diagnostic criteria for MetALD because he has cardiometabolic risk factors (prediabetes, dyslipidemia, hypertension) AND consumes 42 g of alcohol daily, which falls within the MetALD threshold of 30-60 g/day for males 1, 2.

Diagnostic Reasoning

The new steatotic liver disease (SLD) nomenclature, established by multi-society consensus, creates distinct categories based on both metabolic dysfunction and alcohol consumption thresholds 2:

Alcohol Consumption Thresholds Define the Categories:

• MASLD: Requires ≥1 cardiometabolic risk factor AND alcohol consumption below the MetALD threshold (defined as "absence of harmful alcohol intake") 3

• MetALD: Requires ≥1 cardiometabolic risk factor AND alcohol consumption of:

  • Males: 210-420 g/week (30-60 g/day)
  • Females: 140-350 g/week (20-50 g/day) 1, 2

• ALD: Alcohol consumption exceeding MetALD thresholds without necessarily requiring metabolic dysfunction 3

This Patient's Profile:

Cardiometabolic risk factors present:

• Prediabetes
• Dyslipidemia
• Hypertension

Alcohol consumption: 42 g/day (294 g/week)

This places him squarely in the MetALD category—above the MASLD threshold but below the ALD threshold 1.

Why Not the Other Options?

MASLD is incorrect because his alcohol intake (42 g/day) exceeds the threshold that defines "absence of harmful alcohol intake" required for MASLD diagnosis 3.

ALD is incorrect because his alcohol consumption (42 g/day) falls below the typical ALD threshold (>60 g/day for males), and he has clear metabolic dysfunction 1.

NASH/Nonalcoholic steatohepatitis is incorrect because this is outdated terminology that has been replaced by MASH (metabolic dysfunction-associated steatohepatitis), and more importantly, it refers to a histological subtype rather than the overarching disease category 3. Additionally, NASH terminology specifically excluded any significant alcohol use, which this patient has.

Clinical Implications of MetALD

MetALD represents a distinct disease entity with unique prognostic implications 4, 5:

• Higher risk of liver-related events compared to MASLD alone (adjusted HR 1.42) 5
• Increased mortality risk (adjusted HR 1.13) compared to MASLD 5
• More severe liver outcomes and faster disease progression than MASLD 4
• Increased risk of cirrhosis and hepatocellular carcinoma 1

Management Priorities:

The dual nature of MetALD requires addressing both components 1, 4:

1. Alcohol reduction/abstinence is critical
2. Weight loss and lifestyle modification
3. Optimization of cardiometabolic risk factors (continue statin, optimize blood pressure control, address prediabetes)
4. Risk stratification for liver fibrosis using FIB-4 score followed by elastography if indicated 3

Common Pitfall

The critical pitfall is misclassifying this patient as having MASLD simply because he has metabolic risk factors, thereby missing the important contribution of alcohol and the higher risk profile that MetALD confers. The 42 g/day alcohol consumption is not incidental—it fundamentally changes the disease classification and prognosis 5.